EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

被引：0
|
作者：
Wang, L. [1 ]
Su, S. [2 ,3 ]
Lv, X. [2 ,3 ]
Liu, Y. [2 ,3 ]
Chen, F. [2 ,3 ]
Shao, J. [2 ,3 ]
Liu, B. [2 ,3 ]
机构：
[1] Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Clin Canc Inst, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Neoantigen vaccine; EGFR mutation; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.11D.05
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [21] HOW TO MAKE THE CHOICE IN THE REUSE OF EGFR-TKI FOR ADVANCED NSCLC PATIENTS WHO BENEFITED FROM PRIOR GEFITINIB THERAPY: THE ORIGINAL DRUG OR SWITCHING TO A SECOND EGFR-TKI?
    Tang, Chuanhao
    Guo, Wanfeng
    Li, Jianjie
    Wang, Weixia
    Liu, Xiaoqing
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S888 - S889
  • [22] The relationship of EGFR intron 1 (CA) and microsatellite polymorphism and the efficacy of EGFR-TKI in advanced NSCLC patients
    Zhou, S.
    Ren, S.
    Yan, L.
    Zhang, J.
    Zhou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [24] NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
    Facchinetti, Francesco
    Tiseo, Marcello
    Gnetti, Letizia
    Silini, Enrico Maria
    Ardizzoni, Andrea
    LUNG CANCER, 2013, 82 (01) : 177 - 178
  • [25] Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC
    Cheng, Yuan
    Wang, Huan
    Yuan, Wendi
    Wang, Haotian
    Zhu, Yuheng
    Chen, Huanhuan
    Jiang, Wenyan
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2023, 116
  • [26] Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis
    Qin, B.
    Jiao, X.
    Liu, K.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35
  • [27] Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
    Le Guevelou, Jennifer
    Dugue, Audrey
    Richard, Nicolas
    Dubos, Catherine
    Do, Pascal
    Danhier, Serge
    Lerouge, Delphine
    Bonneau, Jessica
    Blanc, Cecile
    Gervais, Radj
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1229
  • [28] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
    Takeda, Masayuki
    Okamoto, Isamu
    Tsurutani, Junji
    Oiso, Naoki
    Kawada, Akira
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
  • [29] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [30] Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells
    Norma, Hernandez-Pedro Y.
    Giovanny, Soca-Chafre
    Mario, Orozco-Morales
    Pedro, Barrios-Bernal
    Oscar, Arrieta
    CANCER RESEARCH, 2018, 78 (13)
12345